Literature DB >> 23088652

Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).

Katrina A Hadfield1, David I Pattison, Bronwyn E Brown, Liming Hou, Kerry-Anne Rye, Michael J Davies, Clare L Hawkins.   

Abstract

Oxidative modification of HDLs (high-density lipoproteins) by MPO (myeloperoxidase) compromises its anti-atherogenic properties, which may contribute to the development of atherosclerosis. Although it has been established that HOCl (hypochlorous acid) produced by MPO targets apoA-I (apolipoprotein A-I), the major apolipoprotein of HDLs, the role of the other major oxidant generated by MPO, HOSCN (hypothiocyanous acid), in the generation of dysfunctional HDLs has not been examined. In the present study, we characterize the structural and functional modifications of lipid-free apoA-I and rHDL (reconstituted discoidal HDL) containing apoA-I complexed with phospholipid, induced by HOSCN and its decomposition product, OCN- (cyanate). Treatment of apoA-I with HOSCN resulted in the oxidation of tryptophan residues, whereas OCN- induced carbamylation of lysine residues to yield homocitrulline. Tryptophan residues were more readily oxidized on apoA-I contained in rHDLs. Exposure of lipid-free apoA-I to HOSCN and OCN- significantly reduced the extent of cholesterol efflux from cholesterol-loaded macrophages when compared with unmodified apoA-I. In contrast, HOSCN did not affect the anti-inflammatory properties of rHDL. The ability of HOSCN to impair apoA-I-mediated cholesterol efflux may contribute to the development of atherosclerosis, particularly in smokers who have high plasma levels of SCN- (thiocyanate).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23088652     DOI: 10.1042/BJ20121210

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  19 in total

Review 1.  Tripping up Trp: Modification of protein tryptophan residues by reactive oxygen species, modes of detection, and biological consequences.

Authors:  Marilyn Ehrenshaft; Leesa J Deterding; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2015-09-21       Impact factor: 7.376

2.  Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase.

Authors:  P E Morgan; R P Laura; R A Maki; W F Reynolds; M J Davies
Journal:  Free Radic Res       Date:  2015-03-27

Review 3.  Why targeting HDL should work as a therapeutic tool, but has not.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

4.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

5.  Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.

Authors:  Joseph A DiDonato; Ying Huang; Kulwant S Aulak; Orli Even-Or; Gary Gerstenecker; Valentin Gogonea; Yuping Wu; Paul L Fox; W H Wilson Tang; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  Circulation       Date:  2013-08-22       Impact factor: 29.690

Review 6.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

7.  Mitochondria-targeted spin traps: synthesis, superoxide spin trapping, and mitochondrial uptake.

Authors:  Micael Hardy; Florent Poulhés; Egon Rizzato; Antal Rockenbauer; Karol Banaszak; Hakim Karoui; Marcos Lopez; Jacek Zielonka; Jeannette Vasquez-Vivar; Savitha Sethumadhavan; Balaraman Kalyanaraman; Paul Tordo; Olivier Ouari
Journal:  Chem Res Toxicol       Date:  2014-06-13       Impact factor: 3.739

8.  An abundant dysfunctional apolipoprotein A1 in human atheroma.

Authors:  Ying Huang; Joseph A DiDonato; Bruce S Levison; Dave Schmitt; Lin Li; Yuping Wu; Jennifer Buffa; Timothy Kim; Gary S Gerstenecker; Xiaodong Gu; Chandra S Kadiyala; Zeneng Wang; Miranda K Culley; Jennie E Hazen; Anthony J Didonato; Xiaoming Fu; Stela Z Berisha; Daoquan Peng; Truc T Nguyen; Shaohong Liang; Chia-Chi Chuang; Leslie Cho; Edward F Plow; Paul L Fox; Valentin Gogonea; W H Wilson Tang; John S Parks; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Nat Med       Date:  2014-01-26       Impact factor: 53.440

Review 9.  Role of Myeloperoxidase in Patients with Chronic Kidney Disease.

Authors:  Bojana Kisic; Dijana Miric; Ilija Dragojevic; Julijana Rasic; Ljiljana Popovic
Journal:  Oxid Med Cell Longev       Date:  2016-04-03       Impact factor: 6.543

10.  Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.

Authors:  Ahmed Bakillah; Fasika Tedla; Isabelle Ayoub; Devon John; Allen J Norin; M Mahmood Hussain; Clinton Brown
Journal:  Mediators Inflamm       Date:  2015-11-15       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.